882 related articles for article (PubMed ID: 27434443)
1. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
Palmer SC; Mavridis D; Nicolucci A; Johnson DW; Tonelli M; Craig JC; Maggo J; Gray V; De Berardis G; Ruospo M; Natale P; Saglimbene V; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque L; Lloyd A; Ahmad N; Liu Y; Tiv S; Wiebe N; Strippoli GF
JAMA; 2016 Jul; 316(3):313-24. PubMed ID: 27434443
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
5. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
6. Metformin monotherapy for adults with type 2 diabetes mellitus.
Gnesin F; Thuesen ACB; Kähler LKA; Madsbad S; Hemmingsen B
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD012906. PubMed ID: 32501595
[TBL] [Abstract][Full Text] [Related]
7. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.
Maruthur NM; Tseng E; Hutfless S; Wilson LM; Suarez-Cuervo C; Berger Z; Chu Y; Iyoha E; Segal JB; Bolen S
Ann Intern Med; 2016 Jun; 164(11):740-51. PubMed ID: 27088241
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.
Qian D; Zhang T; Tan X; Zheng P; Liang Z; Xie J; Jiang J; Situ B
PLoS One; 2018; 13(8):e0202563. PubMed ID: 30148851
[TBL] [Abstract][Full Text] [Related]
9. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
10. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
[TBL] [Abstract][Full Text] [Related]
11. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
McIntosh B; Cameron C; Singh SR; Yu C; Ahuja T; Welton NJ; Dahl M
Open Med; 2011; 5(1):e35-48. PubMed ID: 22046219
[TBL] [Abstract][Full Text] [Related]
12. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.
McIntosh B; Cameron C; Singh SR; Yu C; Dolovich L; Houlden R
Open Med; 2012; 6(2):e62-74. PubMed ID: 23696771
[TBL] [Abstract][Full Text] [Related]
13. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
14. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
[TBL] [Abstract][Full Text] [Related]
15. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
[TBL] [Abstract][Full Text] [Related]
16. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
17. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
18. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis.
Zintzaras E; Miligkos M; Ziakas P; Balk EM; Mademtzoglou D; Doxani C; Mprotsis T; Gowri R; Xanthopoulou P; Mpoulimari I; Kokkali C; Dimoulou G; Rodopolou P; Stefanidis I; Kent DM; Hadjigeorgiou GM
Clin Ther; 2014 Oct; 36(10):1443-53.e9. PubMed ID: 25109773
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Tsapas A; Avgerinos I; Karagiannis T; Malandris K; Manolopoulos A; Andreadis P; Liakos A; Matthews DR; Bekiari E
Ann Intern Med; 2020 Aug; 173(4):278-286. PubMed ID: 32598218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
